Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $9.6100 (2.02%) ($9.1100 - $9.6100) on Tue. May. 11, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.94% (three month average) | RSI | 45 | Latest Price | $9.6100(2.02%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -0.2% a day on average for past five trading days. | Weekly Trend | FOLD declines -2.2% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Value stock sell-off for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(57%) IWO(53%) IWM(50%) XBI(50%) IWC(49%) | Factors Impacting FOLD price | FOLD will decline at least -2.47% in a week (0% probabilities). VIXM(-31%) VXX(-14%) UUP(-11%) UNG(-6%) TLT(-4%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.47% (StdDev 4.94%) | Hourly BBV | 0.2 () | Intraday Trend | 0% | | | |
|
Resistance Level | $9.89 | 5 Day Moving Average | $9.6(0.1%) | 10 Day Moving Average | $9.8(-1.94%) | 20 Day Moving Average | $9.89(-2.83%) | To recent high | -48.6% | To recent low | 4.5% | Market Cap | $2.482b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |